Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research to better understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area.
Location: United States, California, San Francisco
Total raised: $1B
Investors 6
| Date | Name | Website |
| 13.07.2025 | Foresite C... | foresiteca... |
| 16.09.2024 | ARCH Ventu... | archventur... |
| 10.07.2026 | Breyer Cap... | breyercapi... |
| 22.08.2024 | F-Prime Ca... | fprimecapi... |
| 08.05.2024 | WRF Capita... | wrfseattle... |
| 02.01.2025 | Sahsen Ven... | sahsen.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 25.04.2024 | - | $1B | - |
Mentions in press and media 8
| Date | Title | Description |
| 05.05.2026 | Deviation Capital Launches With $2 Billion In AUM Following Spinout From Two Sigma | Deviation Capital, an early-stage venture capital firm, has launched as a newly independent business following the completed spinout of the Two Sigma Ventures operation from quantitative investment and trading firm Two Sigma. As part of the... |
| 02.01.2025 | The Largest AI Startup Funding Deals Of 2024 | 18 Shares Email Facebook Twitter LinkedIn Want to keep track of the largest startup funding deals in 2024 with our curated list of $100 million-plus venture deals to U.S.-based companies? Check out The Crunchbase Megadeals Board. You can al... |
| 25.04.2024 | Xaira Therapeutics: A Billion-Dollar Bet on AI Drug Discovery | In the fast-paced world of tech and biotech, Xaira Therapeutics emerges as a powerhouse with a massive $1 billion in funding. Led by CEO Marc Tessier-Lavigne, a former Stanford president and Genentech chief scientific officer, Xaira is read... |
| 25.04.2024 | Generative AI for Healthcare: Xaira Therapeutics Launches with $1 Billion Funding | Quincy Jon, Tech Times 25 April 2024, 09:04 am ARCH Venture Partners and Foresite Labs, a Foresite Capital subsidiary, announced a revolutionary AI-driven drug discovery effort. With a $1 billion investment, they founded Xaira Therapeutics.... |
| 24.04.2024 | Xaira Therapeutics Launches With Over USD1 Billion in Funding | Xaira Therapeutics, a San Francisco, CA-based integrated AI biotechnology company, launched with more than $1 Billion of committed capital. Backers included ARCH Venture Partners and Foresite Capital, F-Prime, NEA, Sequoia Capital, Lux Capi... |
| 24.04.2024 | Xaira, an AI drug discovery startup, launches with a massive $1B, says it’s ‘ready’ to start developing drugs | Advances in generative AI have taken the tech world by storm. Biotech investors are making a big bet that similar computational methods could revolutionize drug discovery. On Tuesday, ARCH Venture Partners and Foresite Labs, an affiliate of... |
| 23.04.2024 | With ARCH funding, Xaira Therapeutics aims to reinvent drug R&D by using artificial intelligence to deliver transformative medicines | - |
| - | Xaira Therapeutics | “Learning the Language of Life™” |